动态增强CT鉴别胰腺神经内分泌癌与高分化神经内分泌肿瘤的比较研究
该回顾性研究纳入69例病理确诊的胰腺神经内分泌肿瘤患者,采用动态增强CT进行定性和定量分析,以区分神经内分泌癌与高分化神经内分泌肿瘤。多因素分析显示门脉期强化比是唯一独立鉴别因子,门脉期强化比<0.8诊断神经内分泌癌的敏感度为94.1%、特异度为88.5%。
要点
- 门脉期强化比<0.8提示神经内分泌癌,敏感度94.1%、特异度88.5%。
- 神经内分泌癌更常出现主胰管扩张、胆管扩张、血管侵犯,且肿瘤-实质界面差、动脉强化比和门脉期强化比更低。
- 联合三项显著CT特征诊断神经内分泌癌的敏感度为88.2%、特异度为88.5%。
关键影像表现/征象
- 神经内分泌癌主胰管扩张、胆管扩张和血管侵犯的出现频率显著高于高分化神经内分泌肿瘤(p<0.05)。
- 神经内分泌癌的肿瘤-实质界面(delta,即肿瘤显示清晰度)显著低于高分化神经内分泌肿瘤(p<0.05)。
- 神经内分泌癌的动脉强化比和门脉期强化比均显著低于高分化神经内分泌肿瘤(p<0.05)。
诊断标准与关键数值
- 多因素分析显示门脉期强化比是区分神经内分泌癌与高分化神经内分泌肿瘤的唯一独立因子,比值比<0.001(95%CI <0.001-0.012)。
- 门脉期强化比<0.8诊断神经内分泌癌的敏感度为94.1%(95%CI 71.3-99.9),特异度为88.5%(95%CI 76.6-95.6)。
- 联合三项显著CT特征诊断神经内分泌癌的敏感度为88.2%,特异度为88.5%。
临床应用与阅片要点
- 阅片时测量门脉期肿瘤-实质强化比,低于0.8时需考虑神经内分泌癌可能。
- 注意观察主胰管扩张、胆管扩张和血管侵犯等征象,这些征象在神经内分泌癌中更常见。
- 结合定性和定量CT特征综合判断,可提高鉴别神经内分泌癌与高分化神经内分泌肿瘤的准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify CT features distinguishing neuroendocrine carcinomas (NECs) of pancreas from well-differentiated neuroendocrine tumors (NETs) according to the World Health Organization 2017 and 2019 classification systems.
METHODS: This retrospective study included 69 patients with pathologically confirmed pancreatic neuroendocrine neoplasms who underwent dynamic CT (17, 17, 18, and 17 patients for well-differentiated grade 1, 2, 3 NET and NEC, respectively). CT was used to perform qualitative analysis (component, homogeneity, calcification, peripancreatic infiltration, main pancreatic ductal dilatation, bile duct dilatation, intraductal extension, and vascular invasion) and quantitative analysis (interface between tumor and parenchyma [delta], arterial enhancement ratio [AER], portal enhancement ratio [PER], and dynamic enhancement pattern). Uni- and multivariate logistic regression analyses were performed to identify features indicating NEC. Optimal cutoff values for enhancement ratios were determined.
RESULTS: NECs demonstrated significantly higher frequencies of main pancreatic ductal dilatation, bile duct dilatation, vascular invasion, and significantly lower delta (i.e., lower conspicuity), AER, and PER than well-differentiated NET (p < 0.05). On multivariate analysis, PER was the only independent factor selected by the model for differentiation of NEC from well-differentiated NET (odds ratio, < 0.001; 95% confidence interval [CI], < 0.001-0.012). PER < 0.8 showed the sensitivity of 94.1% (95% CI, 71.3-99.9) and the specificity of 88.5% (95% CI, 76.6-95.6). When three significant CT features were combined, the sensitivity and specificity for diagnosing NEC were 88.2% and 88.5%, respectively.
CONCLUSIONS: Tumor-parenchyma enhancement ratio in portal phase is a useful CT feature to distinguish NECs from well-differentiated NETs. Combining qualitative and quantitative CT features may aid in achieving good diagnostic accuracy in the differentiation between NEC and well-differentiated NET.
KEY POINTS: • Neuroendocrine carcinoma of the pancreas should be distinguished from well-differentiated neuroendocrine tumor in line with the revised grading and staging system. • Neuroendocrine carcinoma of the pancreas can be differentiated from well-differentiated neuroendocrine tumor on dynamic CT based on assessment of the portal enhancement ratio, arterial enhancement ratio, tumor conspicuity, dilatation of the main pancreatic duct or bile duct, and vascular invasion. • Tumor-parenchyma enhancement ratio in portal phase of dynamic CT is a useful feature, which may help to distinguish neuroendocrine carcinoma from well-differentiated neuroendocrine tumor of the pancreas.
引用
- Park HJ, Kim HJ, Kim KW, et al. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol. 2020. PMID: 32346794. doi:10.1007/s00330-020-06867-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。